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Abstract: Mucopolysaccharidosis type I (MPS I) is an autosomal disease caused by 
alpha-l-iduronidase (IDUA) deficiency. This study used IDUA knockout mice as a model to 
evaluate whether parameters such as dose of plasmid and time of treatment could influence the 
transfection efficiency of complexes formed with PEGylated cationic nanoemulsions and plasmid 
(pIDUA), which contains the gene that encodes for IDUA. Formulations were composed of 
medium chain triglycerides, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-(amino[polyethylene glycol]-2000), 1,2-dioleoyl-sn-
glycero-3-trimethylammonium propane (DOTAP), glycerol, and water and were prepared by 
the adsorption or encapsulation of preformed pIDUA–DOTAP complexes by high-pressure 
homogenization. A progressive increase in IDUA expression was observed with an increase in the 
dose and time of transfection for mice treated with both complexes (adsorbed and encapsulated), 
especially in the liver. Regardless of the complex administered, a significant increase in IDUA 
activity was detected in lungs and liver compared with nontreated MPS I when a dose of 60 µg 
was administered and IDUA activity was measured 7 days postadministration. Tissue sections 
of major organs showed no presence of cell necrosis, inflammatory infiltrate, or an increase in 
apoptosis. Furthermore, immunohistochemistry for CD68 showed no difference in the number 
of macrophage cells in treated and nontreated animals, indicating the absence of inflammatory 
reaction caused by the treatment. The data set obtained in this study allowed establishing that 
factors such as dose and time can influence transfection efficiency in different degrees and that 
these complexes did not lead to any lethal effect in the MPS I murine model used.
Keywords: cationic nanoemulsions, DSPE-PEG, MPS I, plasmid, pIDUA
Introduction
Gene therapy has emerged as a promising strategy for a wide range of inherited and 
acquired diseases.1 For successful gene therapy, genes have to be delivered to the 
nucleus of target cells in a safe and effective manner. In the past few decades, a number 
of viral and nonviral carriers that can be used to transfer foreign genetic material into 
cells have been developed aimed at enhancing gene transfer in vitro and in vivo.2,3 
Viral vectors have been widely used to achieve efficient gene transfer. However, issues 
related to safety, risk of insertional mutagenesis, and the strong immune response 
generated by these vectors have limited their application.1
Nonviral gene carriers have been extensively investigated as alternatives to viral 
vectors for gene delivery since they offer considerable advantages such as safety and 
easy production.3,4 Cationic nanoemulsions have been considered as potential nonviral 
nucleic acid delivery systems.5 We recently described the design of PEGylated cationic 
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nanoemulsions as a delivery system for a plasmid containing 
the gene that codes for α-l-iduronidase (pIDUA).6 A defi-
ciency of this enzyme results in the lysosomal storage of the 
glycosaminoglycans, thereby causing the lysosomal storage 
disorder mucopolysaccharidosis type I (MPS I). The overall 
results showed that intravenous administration of pIDUA/
PEGylated cationic nanoemulsions (obtained by adsorption or 
encapsulation of preformed pIDUA-cationic lipid complexes) 
can significantly increase IDUA activity and expression in 
different organs, especially in the lungs and liver.7
Some well-documented studies have demonstrated that 
the single or multiple intravenous administration of cationic 
lipid–DNA complexes is often related to a dose- or time-
dependent effect, in terms of transfection efficiency and tox-
icity, especially in the liver and lungs.8–10 Similarly, the aim of 
this study was to evaluate the effect of the dose (30 and 60 µg) 
and time (2 or 7 days postinjection) on transfection efficiency 
of pIDUA/PEGylated cationic nanoemulsion complexes 
in a MPS I murine model. The gene expression and IDUA 
activity were evaluated after the intravenous administration 
of complexes obtained by the adsorption or encapsulation of 
preformed pIDUA–cationic lipid complexes into the oil phase 
of nanoemulsions. The potential toxicity of such complexes 
on main organs (ie, lungs, spleen, liver, and kidneys) was 
also evaluated.
Materials and methods
Materials
Medium-chain triglycerides (MCTs), 1,2-dioleoyl- 
sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-
sn-glycero-3-trimethylammonium propane (DOTAP), 
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
(amino[polyethylene glycol]-2000) (DSPE-PEG) were pur-
chased from Lipoid (Ludwigshafen, Germany). Glycerol and 
chloroform were obtained from Merck (Rio de Janeiro, Brazil). 
4-Methylumbelliferylalpha-l-iduronide was purchased from 
Glycosynth (Warrington, UK), and TRIzol® Reagent was pur-
chased from Thermo Fisher Scientific (Waltham, MA, USA). 
Platinum SYBR Green qPCR SuperMix-UDG kit was obtained 
from Thermo Fisher Scientific, and High-Capacity cDNA 
Reverse Transcription Kit was purchased from Thermo Fisher 
Scientific. All other chemicals were of analytical grades.
Preparation of PEGylated cationic 
nanoemulsions
Blank formulations were composed of 1.6% (w/w) MCT, 
0.364% (w/w) DOPE, 0.036% (w/w) DSPE-PEG, 0.028% 
DOTAP, 2.25% (w/w) glycerol, and Milli-Q® water up to 
100% (PEGylated nanoemulsion [NEP]). The lipids were 
dissolved in chloroform and evaporated under reduced pres-
sure (50°C). The lipid film was hydrated with the water phase 
containing glycerol, vortexed for 3 min, and left overnight. 
Next day, the formulations were vortexed for another 2 min 
and sonicated for 15 min at 37°C. Finally, the emulsions were 
passed through high-pressure homogenization equipment at 
10,000 psi for 10 cycles.
Preparation of pIDUA/PEGylated cationic 
nanoemulsion complexes
The plasmid pIDUA containing the human IDUA cDNA 
under the control of pCMV promoter was associated with 
nanoemulsions either by adsorption (NEP/pIDUA
A
) on NEP 
or by incorporation of hydrophobic pIDUA–DOTAP com-
plex into formulations during the nanoemulsion preparation 
(NEP/pIDUA
E
). For the adsorption of pIDUA, a solution of 
pIDUA was added to nanoemulsions at room temperature 
and left for 30 min. For the encapsulation of pIDUA, the 
hydrophobic pIDUA/DOTAP complex (prepared as previ-
ously described in detail by Fraga et al7) was added into the 
lipid mixture during nanoemulsion preparation followed by 
the high-pressure homogenization procedure. NEP/pIDUA
A
 
and NEP/pIDUA
E
 were prepared at +4/− charge ratio (charge 
ratio of cationic lipid/DNA phosphate groups).
Physicochemical characterization
The droplet size, polydispersity index, and ζ-potential of 
blank PEGylated nanoemulsion and complexes were deter-
mined by photon correlation spectroscopy (PCS) at 90° and 
electrophoretic mobility (3000HS Zetasizer). The samples 
were adequately diluted and analyzed just after preparation 
and after 2 months of storage at 4°C.
In vivo experiments
Experiments were performed as previously described by Fraga 
et al.6,7 Briefly, four groups of mice (4–6 months) received 
200 µL of complexes containing 30 or 60 µg of pIDUA 
obtained by adsorption (NEP/pIDUA
A
, n=3/group) or encapsu-
lation (NEP/pIDUA
E
, n=3/group) through intravenous injection 
in the tail vein. We compared these groups with nontreated MPS 
I mice of same age (MPS I, n=5). Animals were euthanized 
2 (60 µg) or 7 days (30 and 60 µg) after injection by cervical 
dislocation under anesthesia. Liver, lungs, kidneys, and spleen 
were isolated, and a piece of each was flash frozen in liquid 
nitrogen for biochemical analysis and mRNA extraction, with 
the rest used for histology. Before euthanizing the mice, serum 
was collected by retroorbital puncture. Data of mice receiving 
30 µg and euthanized 2 days postinjection were compared with 
our previous work, which followed the same protocol.7
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Gene expression assay to evaluate IDUA transcription 
levels from the plasmid was performed by real-time poly-
merase chain reaction with Platinum SYBR Green qPCR 
SuperMix-UDG kit. Approximately 30 mg of flash frozen 
tissues were used for mRNA extraction with TRIzol® Reagent, 
and the conversion of RNA to cDNA was performed using 
High-Capacity cDNA Reverse Transcription Kit. GAPDH was 
used as a reference gene to account for any variance in the qual-
ity of mRNA and the amount of input cDNA. The following 
primers were used: forward IDUA 5′-CACTGGCTGCTGGA 
GCTT-3′, reverse IDUA 5′-GCTCAAACCCTGGGAGGA-3′; 
forward GAPDH 5′-CCCATCACCATCTTCCAGG-3′, 
reverse GAPDH 5′-CATATTTGGCAGCTTTCTCC-3′. The 
polymerase chain reaction was carried out according to the 
manufacturer’s instructions, and the results were presented as 
described by Livak and Schmittgen.11
For IDUA activity measurements, ~30 mg of tissues 
were homogenized in distilled water. IDUA activity assay 
was performed incubating protein extracts with fluorescent 
substrate 4-methylumbelliferyl α-l-iduronide at 37°C for 1 h 
in sodium formate buffer (pH 2.8) with some modifications.12 
Fluorescence was measured at 365 nm (excitation) and 
450 nm (emission) using a fluorescence spectrophotometer, 
SpectraMax M2. Results are expressed as nanomole per hour 
per milligram of protein. Protein content was measured using 
the method described by Lowry et al.13
Histological analysis
Tissues were fixed in buffered formalin and processed and 
embedded in paraffin wax. Thin cross-sections were submitted 
to routine histological processing, stained with hematoxylin–
eosin (H–E), and analyzed for signs of toxicity.
Immunohistochemistry
Immunohistochemistry for CD68 was performed in kidneys, 
liver, spleen, and lungs samples using specific antibody 
(mouse polyclonal anti-CD68; Abcam, Cambridge, UK). 
A horseradish peroxidase-conjugated antirabbit IgG was 
used as secondary antibody. The slides were analyzed by 
a researcher blinded to the groups. Cells positively stained 
for CD68 were analyzed in 3–5 fields per slide, with a 200× 
magnification. Results are expressed as the number of CD68-
positive cells per square millimeter of tissue sections.
Ethics
All experiments were approved by the ethics committee of 
our institution (Research Ethics Committee of Hospital de 
Clínicas de Porto Alegre – permit numbers 09-0334 and 
12-0477). Animal procedures were carried out in accordance 
with the recommendations in the Guide for the Care and Use 
of Laboratory Animals of the National Institutes of Health, 
monitored by our veterinarian, and designed to minimize 
animal suffering.
statistics
Results are expressed as the mean ± standard error of the mean 
(SEM). Differences were considered to be significant at P0.05. 
Analysis of the data was performed using Student’s t-test on 
IBM® SPSS® Statistics, v 18.0 (Quarry Bay, Hong Kong).
Results
Physicochemical characterization
Table 1 exhibits the droplet size, polydispersity index, and 
ζ-potential of NEP/pIDUA
A
 and NEP/pIDUA
E
.
As can be seen, the high-pressure homogenization pro-
cedure yielded monodisperse nanoemulsions (polydispersity 
index 0.2), exhibiting a mean droplet size of ~200–300 nm. 
Regardless of the method of incorporation (NEP/pIDUA
A
 
or NEP/pIDUA
E
), an inversion of ζ-potential was detected 
from +30 to ~−10 mV. Such a result suggests that, at least 
partially, a part of the plasmid pIDUA is located at the 
oil/water interface of nanoemulsions.
In vivo experiments
Figure 1 exhibits the relative expression of IDUA by quantita-
tive real-time polymerase chain reaction in different organs 
(lungs, spleen, liver, and kidneys) of MPS I mice. The Ct 
value of nontreated MPS I mice for IDUA expression was 
used to calibrate relative expression calculations (varied from 
38 to 40). IDUA was expressed in main organs of treated MPS 
I mice. As shown in Figure 1, IDUA expression was higher 
in the lungs when the dose was increased from 30 to 60 µg 
and it was maintained after 7 days postinjection in animals 
treated with NEP/pIDUA
A
 (1A). A progressive increase in 
IDUA expression was observed with an increase in the dose 
and time of transfection for mice treated with both complexes 
(NEP/pIDUA
A
 and NEP/pIDUA
E
), especially in the liver and 
kidneys. A higher IDUA expression in the spleen was detected 
in animals treated with 30 and 60 µg of pIDUA 7 days after 
the injection, regardless of the complex administered.
Table 1 Physicochemical properties of blank nanoemulsion and 
complexes
Code Droplet size (nm) PI ζ-potential (mV)
NeP 225.8±1.5 0.10±0.06 +14.1±1.4
NeP/pIDUaa 263.9±20.2 0.05±0.03 −9.8±6.7
NeP/pIDUae 242.5±2.1 0.12±0.04 −8.4±1.1
Note: Results represent the mean ± standard deviation of three experiments.
Abbreviations: NEP, PEGylated nanoemulsion; PI, polydispersity index.
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In similar experimental conditions, IDUA activity was 
measured in the main organs and compared with nontreated 
MPS I mice, which were used as negative controls (Table 2). 
The results showed an increased IDUA activity in the lungs 
after the injection of 30 µg after 2 days postadministration 
(1.36 nmol/h/mg of protein) for NEP/pIDUA
A
.
Regardless of the complex administered, a significant 
increase in IDUA activity (P0.05) was detected in lungs 
and liver compared with nontreated MPS I when a dose of 
60 µg was administered and IDUA activity was measured 
7 days postadministration. Furthermore, significant IDUA 
activity (P0.05) was present in the liver in all treatment 
conditions in accordance with the increase in IDUA expres-
sion in this organ.
Histological and immunohistochemistry 
analysis
Finally, the potential toxicity of pIDUA/PEGylated cationic 
nanoemulsion complexes was evaluated in dissected major 
organs, such as liver, lungs, kidneys, and spleen, 7 days 
postadministration of 60 µg of pIDUA (Figures 2 and 3). 
Tissue sections of major organs showed no presence of cell 
necrosis, inflammatory infiltrate, or an increase in apoptosis. 
Only mild hydropic degeneration was detected in the liver 
when compared with nontreated MPS I mice, regardless of 
the type of complex (NEP/pIDUA
A
 or NEP/-pIDUA
E
) that 
was administered intravenously (Figure 2). Immunohis-
tochemistry for CD68, a macrophage lineage cell marker, 
showed no quantitative difference (P0.05) in the number 
of these cells in treated and nontreated animals, indicating 
the absence of inflammatory reaction caused by the treat-
ment (Figure 3).
Discussion
We have recently described an increase in IDUA activity 
and expression in different organs after the intravenous 
administration of pIDUA/PEGylated cationic nanoemul-
sion complexes.7 However, in this study, our aim was to 
investigate the effect of dose and time on these parameters. 
Figure 1 relative expression of IDUA by real-time RT-qPCR in different organs of MPS I mice treated with NEP/pIDUAa (A) and NeP/pIDUae (B).
Notes: Mice were treated with 30 µg of pIDUA (dark gray bars) or 60 µg of pIDUA (light gray bars) and euthanized 2 days after intravenous injection or 30 µg of pIDUA 
(medium gray bars) or 60 µg of pIDUA (white bars) and euthanized 7 days after intravenous injection. Nontreated MPS I mice were used as control (black bars). Expression 
ratios are relative to GAPDH endogenous control. Values represent the mean ± standard error of the mean and are presented in log scale. *Difference between treated and 
nontreated MPs I mice (student’s t-test, P0.05). #Data from Fraga et al.7
Abbreviations: MPS I, mucopolysaccharidosis type I; RT-qPCR, quantitative real-time polymerase chain reaction.
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Table 2 IDUA activity in different organs of MPS I mice treated 
with NEP/pIDUAa or NeP/pIDUae
Treatment IDUA activity (nmol/h/mg of protein)
Lung Spleen Liver Kidney
30 µg/2 daysa
NeP/pIDUaa 1.36±0.13* 0.10±0.01 0.73±0.03* 0.59±0.10*
NeP/pIDUae 0.39±0.07 0.17±0.02* 1.10±0.03* 0.59±0.02*
30 µg/7 days
NeP/pIDUaa 0.24±0.02 0.10±0.02 0.52±0.07 0.18±0.04
NeP/pIDUae 0.27±0.04 0.09±0.03 0.67±0.09* 0.18±0.01
60 µg/2 days
NeP/pIDUaa 0.28±0.03 0.14±0.01 0.48±0.06 0.24±0.03
NeP/pIDUae 0.27±0.05 0.18±0.05 0.61±0.03* 0.28±0.03
60 µg/7 days
NeP/pIDUaa 0.41±0.04* 0.12±0.05 0.55±0.05* 0.29±0.10
NeP/pIDUae 0.42±0.06* 0.03±0.008 0.54±0.04* 0.23±0.03
MPs I (nontreated) 0.26±0.02 0.10±0.01 0.35±0.06 0.25±0.03
Notes: Results represent the mean ± standard error of the mean. *Difference between 
treated and nontreated MPs I mice (student’s t-test, P0.05). aData from Fraga et al.7
Abbreviations: MPS I, mucopolysaccharidosis type I; NEP, PEGylated nanoe-
mulsion.
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Since transfection efficiency is a measure prone to many 
variable factors, including those related to the properties 
of vectors, in this study, we evaluated the physicochemical 
properties of complexes.
The results of physicochemical properties are in agree-
ment with those observed in our previous studies.6,7 The main 
physicochemical properties of complexes remained similar 
after 60 days of storage at 4°C. This could be related to the 
stability provided by the PEG moiety of DSPE-PEG, since 
its steric hindrance may prevent the aggregation and neu-
tralization of positive charge of pIDUA/PEGylated cationic 
nanoemulsion complexes.14
To assess the carrier’s ability to efficiently transfect cells 
in vivo, the relative quantification of IDUA and GAPDH 
gene expressions in the organs of animals in the treatment 
groups was performed using cDNA samples from differ-
ent tissues. Mice were treated with NEP/pIDUA
A
 or NEP/
pIDUA
E
 at a final dose of 30 or 60 µg and euthanized 2 or 
7 days postinjection. Animals treated with 30 µg of pIDUA 
and euthanized 2 days after the injection were from our 
previous work, performed under the same conditions,7 and 
were included in this study for comparison purposes. That 
allowed us to show a progressive increase in IDUA expres-
sion with an increase in the dose and time of transfection, for 
mice treated with both complexes (NEP/pIDUA
A
 and NEP/
pIDUA
E
). Information about the effect of time and dose can 
vary greatly in the literature and depends on the model used. 
Our results follow in line with those reported by Kim et al8 
and Yoo et al,10 in which an increase in pDNA dose leads to 
higher gene expression, showing that an effect of dose and 
time seems to occur.
We have previously speculated that the increased IDUA 
activity in the lungs 2 days after the administration of 30 µg 
of NEP/pIDUA
A
 results from a possible lung embolization 
??????????
???
?
???
???
????
?
???
???
?????????? ?????
Figure 2 Representative histological sections stained with H–E of different organs of treated groups (NEP/pIDUAa and NeP/pIDUae) and of negative control (MPS I).
Notes: Scale bars in figure represent 100 µm. Magnification ×200.
Abbreviations: H–E, hematoxylin–eosin; MPS I, mucopolysaccharidosis type I; NEP, PEGylated nanoemulsion.
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Figure 3 CD68 immunohistochemistry.
Notes: (A) Representative sections of different organs of treated groups (NEP/pIDUAa and NeP/pIDUae) and negative control (MPS I). Magnification ×200. (B) Quantification 
of CD68-positive cells per millimeter square of tissue. Treated mice are in dark gray bars, and nontreated MPS I mice are in black bars. Values represent the mean ± standard 
error of the mean.
Abbreviations: MPS I, mucopolysaccharidosis type I; NEP, PEGylated nanoemulsion.
of this complex that was not observed when pIDUA was 
encapsulated (NEP/pIDUA
E
).7
Although previous studies have shown that a dose of 
60 µg of pDNA in a similar formulation using DOTAP can 
cause a widespread toxicity and architectural damage9 and 
these authors also used a charge ratio of +4/−, our histologi-
cal and immunohistochemistry evaluations did not show any 
signs of toxicity of the evaluated complexes on the MPS I 
mice model at this plasmid dose; maybe this difference was 
due to the use of DSPE-PEG in our formulation.
Conclusion
The set of results demonstrates that dose and time might have 
an effect on transfection efficiency to a different extent in 
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each organ. In the lungs, the expression and activity were 
influenced by the mode by which pIDUA was associated 
with PEGylated cationic nanoemulsions. A significantly 
higher IDUA gene expression and IDUA activity were 
detected in the liver 7 days postadministration of the highest 
pIDUA dose. In these conditions, there was no evidence of 
a deleterious effect of the complexes on different organs of 
MPS I mice.
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